Escitalopram ist für viele Psychiater das Antidepressivum der ersten Wahl geworden. Es ist das reine, wirksame S-Enantiomer von Citalopram und bietet bei halber Dosierung die gleiche – oder sogar bessere – Wirksamkeit bei potenziell weniger Nebenwirkungen.
.gif)
Never stop escitalopram suddenly — always taper over weeks. This article does not replace psychiatric advice. For suicidal thoughts: Samaritans 116 123 (free, 24/7).
Escitalopram is today the most widely prescribed antidepressant and is considered by psychiatrists as a first-line medication for depression and anxiety disorders. It is the pharmacologically "refined" successor to citalopram — equivalent effect at half the dose, lower QT risk, broader licensing. One important feature: escitalopram is metabolised by the liver enzyme CYP2C19, which is also inhibited by omeprazole. Anyone taking both will have higher escitalopram blood levels — with increased QT risk.
| Property | Details |
|---|---|
| Active substance | Escitalopram (S-enantiomer of citalopram) |
| ATC code | N06AB10 |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Available forms | Film-coated tablets 5 / 10 / 15 / 20 mg; oral drops |
| Half-life | approx. 27–32 hours |
| Bioavailability | approx. 80% |
| Metabolism | CYP2C19 + CYP3A4 (note: omeprazole!) |
| Intake | Once daily, independent of meals |
| Onset of action | 2–4 weeks |
| Prescription only | Yes |
| Equivalent dose | 10 mg escitalopram ≈ 20–40 mg citalopram |
This is by far the most frequent question about escitalopram — and the pharmacological answer is elegant. Citalopram consists chemically of two mirror-image molecules: the R-enantiomer and the S-enantiomer. This 50:50 mixture is called a racemate. The problem: only the S-enantiomer has antidepressant activity. The R-enantiomer contributes little to the therapeutic effect but is partly responsible for QT prolongation. Escitalopram is the isolated, pure S-enantiomer — the active molecule extracted and the inactive portion removed.
The result: 10 mg escitalopram works comparably to 20–40 mg citalopram — with less QT prolongation and broader licensing for five indications rather than two. The Cipriani meta-analysis in the Lancet (2009) also showed a slight efficacy advantage for escitalopram over other SSRIs. For patients currently taking citalopram and doing well on it, there is no compelling reason to switch. For new starts, escitalopram is today clearly preferable.
| Escitalopram | Citalopram | |
|---|---|---|
| Chemistry | Pure S-enantiomer | Racemate (R+S mixture) |
| Active fraction | 100% | approx. 50% (S-fraction only) |
| Standard dose | 10 mg | 20 mg |
| Maximum dose | 20 mg (10 mg in older adults) | 40 mg (20 mg in older adults) |
| QT prolongation | Lower (4.3 ms at 10 mg) | Greater (10–20 ms) |
| Licensed indications | 5 | 2 |
| Cipriani meta-analysis 2009 | Slight efficacy advantage | No advantage |
| CYP interaction potential | Similar (CYP2C19) | Slightly higher |
| Price (generics) | Comparable | Comparable |
Escitalopram selectively blocks the serotonin transporter (SERT) — the protein that takes serotonin back up into the releasing nerve cell after it has been released. The blockade allows serotonin to remain in the synaptic cleft longer, stimulating downstream receptors more intensely. Serotonin activity in the brain increases — producing mood-lifting, anxiolytic, and drive-enhancing effects.
As with the related citalopram: the increase in serotonin occurs immediately, but the actual antidepressant effect only develops through the gradual desensitisation of receptors — a process that takes 2–4 weeks. This is why side effects can occur in the first weeks without any improvement in mood yet.
Escitalopram has five licensed indications — significantly more than citalopram. One important dosing principle applies to all anxiety disorders: always start at 5 mg. Patients with panic disorder frequently react paradoxically at first with heightened anxiety. Anyone starting at 10 mg may find the therapy intolerable and discontinue — when gradual initiation would have been well tolerated.
| Indication | Starting dose | Standard dose | Maximum dose |
|---|---|---|---|
| Depression | 5–10 mg | 10 mg | 20 mg |
| Panic disorder | 5 mg (!) | 10 mg | 20 mg |
| Generalised anxiety disorder | 10 mg | 10 mg | 20 mg |
| OCD | 5–10 mg | 10–20 mg | 20 mg |
| Social phobia | 5–10 mg | 10 mg | 20 mg |
| Older adults (>65 years) | 5 mg | 5–10 mg | 10 mg (!) |
| Hepatic impairment | 5 mg | 5–10 mg | 10 mg |
Escitalopram prolongs the QT interval on the ECG — less than citalopram, but clinically relevant enough to have prompted an MHRA safety warning in 2011. The QT prolongation is dose-dependent: at 10 mg it is 4.3 ms — at supratherapeutic doses of 30 mg it is 10.7 ms. The risk is therefore considerably lower than with citalopram (10–20 ms), but an ECG at the start of therapy and in at-risk groups remains advisable.
The combination with electrolyte disturbances is particularly dangerous: potassium depletion from diuretics such as torasemide, or magnesium depletion from long-term pantoprazole therapy, substantially increase QT risk. Anyone taking escitalopram together with a diuretic or PPI should have electrolytes monitored regularly.
| Risk group | Recommendation |
|---|---|
| Pre-existing long QT syndrome | Contraindicated! |
| Older adults > 65 years | Maximum 10 mg; ECG recommended |
| Hepatic impairment | Maximum 10 mg |
| QT-prolonging co-medication (macrolides, antipsychotics) | Contraindicated! |
| Hypokalaemia / hypomagnesaemia | Correct electrolytes first! Note: torasemide / pantoprazole |
Escitalopram's side effects follow a predictable pattern — and knowing this pattern prevents premature discontinuation.
In the first 1–2 weeks, adjustment reactions predominate: nausea, inner restlessness, sleep disturbances, and headaches. These symptoms arise because the brain is responding to the sudden increase in serotonin and adapting. They resolve for most patients after 1–2 weeks. Anyone experiencing nausea should take escitalopram with food — this reduces gastric irritation.
From the second week, mood typically begins to lift, anxiety recedes, and motivation returns. The initial side effects subside. A doctor's appointment during this phase is worthwhile to evaluate the dose — some patients need 10 mg long-term, others need an increase to 20 mg.
Sexual dysfunction and emotional blunting are the most common long-term complaints and are rarely raised spontaneously. Emotional blunting — the feeling of no longer properly experiencing joy or sadness — is described by some patients as worse than the original depression. Night sweats are also common and frequently persistent. All these long-term side effects should be actively raised with the doctor — options exist (dose reduction, switching to bupropion or vortioxetine).
40–70% of all SSRI users develop sexual dysfunction — making this the most common side effect that is least frequently raised. Reduced libido, delayed ejaculation, anorgasmia, and erectile dysfunction can affect any patient, regardless of age or sex. The problem is often left unspoken because the subject is uncomfortable, or because patients assume it is simply "a consequence of the treatment".
This assumption is wrong. Several strategies are available: a careful dose reduction often helps — if depression remains stable with it. Switching to bupropion (not an SSRI, barely any sexual side effects) or vortioxetine may be appropriate. Mirtazapine also has fewer sexual side effects, but frequently causes weight gain. The most important step: raise the subject with the doctor. Sexual side effects are rarely actively asked about in medical consultations — patients need to bring the topic up themselves.
A serious, rare but real phenomenon: in a small proportion of patients, sexual dysfunction persists even after stopping escitalopram — sometimes for months or years. This so-called Post-SSRI Sexual Dysfunction (PSSD) is scientifically documented and was acknowledged by the EMA in 2019. The mechanism is not yet fully understood. The risk is rare, but every patient taking SSRIs should be aware of it — and consult their doctor if complaints persist after stopping.
Stopping escitalopram is for many patients the most difficult part of the entire treatment. Abrupt discontinuation leads to discontinuation symptoms in a significant proportion of patients — brain zaps, dizziness, nausea, irritability, and sleep disturbances. This is not because escitalopram is addictive, but because the brain has adapted to elevated serotonin levels and needs time to recalibrate.
The mechanism is the same as with citalopram: serotonin transporter blockade does not behave linearly with dose. The step from 5 mg to zero is pharmacologically more dramatic than from 20 to 10 mg — because the last few milligrams account for a disproportionately large share of transporter blockade. The final step must therefore be taken particularly slowly. Oral drops allow doses of 2–3 mg and are very valuable during this phase.
| Phase | Dose | Duration |
|---|---|---|
| Phase 1 | 20 mg → 15 mg | 2–4 weeks |
| Phase 2 | 15 mg → 10 mg | 2–4 weeks |
| Phase 3 | 10 mg → 5 mg | 2–4 weeks |
| Phase 4 | 5 mg → stop | 2–4 weeks |
| Phase | Dose | Duration |
|---|---|---|
| Phase 1 | 10 mg → 5 mg | 2–4 weeks |
| Phase 2 | 5 mg → stop (or 5 mg every other day) | 2–4 weeks |
